Drugs Flashcards
Typical vs atypical antipsychotics and their effect on dopamine receptors
• D1-like are coupled to stimulatory G-protein Gs and have a stimulatory
effect on neurotransmission
• The D2-like are coupled to inhibitory Gi proteins, and have an inhibitory
effect on neurotransmission
Typical (1st generation)
• High affinity for D2 receptors
• Effective for +ve symptoms
• Do little for –ve symptoms
• Cause movement and motor side effects (as they block dopamine receptors)
• Haloperidol, Zuclopenthixol, Flupentixol, Chlorpromazine, Fluphenazine
Atypical (2nd generation)
• Higher affinity for 5HT-2 receptors than D2 receptors
• Richer pharmacology
• Effective for +ve symptoms
• Do more for –ve symptoms
• More significant metabolic ADRs
• Quetiapine, Risperidone, Olanzapine, Clozapine, Aripiprazole, Paliperidone
Lurasidone
Risperidone
• Risperidone
– first ‘atypical’ on the market
– antagonist at 5HT2a, 5HT2c, alpha 1, D2
– hypothesis that the 5HT blockade mitigates against
EPSE – dose dependent
– also available as depot injection
– Oral is generic
Quetiapine
• Quetiapine
– Alpha 1 blockade causes postural hypotension when starting (use low starting dose and titrate)
– very low incidence of hyperprolactinemia
– Available as a once daily MR product
– Both formulations generic
Olanzapine
• Olanzapine
– antagonist at assorted DA and 5HT receptors
– also at H1 receptors: weight gain & drowsiness
– dyslipidaemia, diabetes
– also available as olanzapine pamoate depot – care
due to ‘post-injection syndrome’
– generic as orodispersible also
Typical antipsychotic examples
Haloperidol,
Zuclopenthixol,
Flupentixol,
Chlorpromazine,
Fluphenazine
Atypical antipsychotic examples
Quetiapine,
Risperidone,
Olanzapine,
Clozapine,
Aripiprazole,
Paliperidone,
Lurasidone
Treatment resistance options for schizophrenia
Have to have tried 2 antipsychotics with compliance and length
• Around a third of people with schizophrenia are described as treatment
resistant
• What does this mean?
• Clozapine & Depots
• BNF Maximum Doses
• Psychology input
Clozapine
Clozapine
– The ONLY drug licensed for treatment-
resistant schizophrenia
– 1% incidence of neutropenia/agranulocytosis (check FBC)
• mandatory registration of patient, prescriber and dispenser with appropriate monitoring service
• baseline FBC, then weekly for 18 weeks, fortnightly for 1 year, then every four weeks for the duration of treatment
• Avoid other agranulocytosis-causing drugs, e.g.
carbamazepine
• Dose titration & re-titration after 48hours
Clozapine side effects
– Unpleasant side effect profile
• postural hypotension
• drowsiness
• weight gain
• ?diabetes
• hypersalivation
• constipation N.B. has caused fatalities
• seizures, esp above 600mg/day ?consider valproate
Smoking cigarettes increases metabolism so if patients come into hospital and stop smoking factor this in with dose
Side effects of anti psychotics
Extra pyramidal:
Dystonia
Pseudo Parkinsonism
Akathisia (inability to remain still)
Tardive dyskinesia
Other side effects:
Cardio toxic
Lower seizure threshold
Weight gain
Sedation
High prolactin
Dry mouth
Metabolic syndrome
Postural hypotension
Constipation
NMS (neuroleptic malignant syndrome)
Management of the side effect of antipsychotics - acute dystonia
– a slow, contained muscular
contraction involving
• neck
• jaw
• tongue
• eye muscles (oculogyric crisis)
• eyelids (blepharospasm)
• glossopharyngeal (speaking,
swallowing problems)
• Treatment: procyclidine 5mg p.o.
– Consider syrup if jaw is locked
– consider I.M. (10mg) if warranted
Acute akathisia side effect management
• A subjective feeling of muscular discomfort and restlessness
– agitation, dysphoria,
– pacing
– standing and sitting in
rapid succession
• Symptoms are primarily motor, and difficult for the patient to control
• Treatment
– reduce antipsychotic dose/change drug
– antimuscarinics are not very effective
– ? Use of propranolol or benzodiazepine
Neuroleptic induced parkinsonism side effect management
Neuroleptic induced parkinsonism
• Muscle stiffness
– ‘lead pipe’ or ‘cogwheel’
• shuffling gait
• stooped posture
• drooling
• ‘mask-like’ face, perioral tremor
• coarse tremor
Treatment
– Rx antimuscarinics at lowest effective dose
– withdraw after 4-6 weeks
• tolerance to this SE can develop
• 50% of patients might need ongoing antimuscarinic Rx
– Can persist for 2/52 to 3/12 after withdrawal of antipsychotics
Neuroleptic Malignant Syndrome
• Rare but can be fatal (1 in 10 die) - rapid changes in dopamine blockade
• Watch out for rigidity, hyperthermia, tachycardia, sweating, fluctuating
consciousness, raised CK (creatinine kinase)
• STOP antipsychotic and initiate specialist treatment
Usually when dose titrated up too much
Dehydrated
Organic brain disease
Alcoholism
Hyperthyroidism
• Mood and behaviour
– muscular rigidity
– dystonia
– agitation
– akinesia
– mutism
– changes in level of
consciousness
• Autonomic effects
– hyperpyrexia (usually
over 38C)
– sweating
– pallor
– tachycardia, BP
fluctuations
– incontinence of urine
• Lab Results
– Raised white blood cell counts
– Raised serum creatinine phosphokinase
– Raised serum myoglobin
Management of NMS
• Discontinue ALL antipsychotics
– Other drugs which might be implicated include
• Antidepressants
• Lithium
• Antiepileptics
– Benzodiazepines are not associated with NMS
• A suitable drug of this class may be used for seizure prophylaxis, management of agitation until the syndrome abates
• Refer to Physician
• medical support measures
– possible Rx of iv dantrolene (muscle relaxant) or oral bromocriptine (DA
agonist)
– treat for 5-10 days as appropriate
Antipsychotic counselling
Antipsychotic Counselling
• Starting treatment what to expect
• How to take
• How long to start working?
• Don’t just stop – and why?
• Risk of relapse upon discontinuation
• Possible side effect and what to do if they occur
• Signposting – for information